Is Immunovant, Inc. (IMVT) a Buy, Sell, or Hold?
NASDAQ : IMVT
Immunovant, Inc. — Analyst Ratings
$38.9 USD
-$1.19 (-2.97%)
- Volume
- 897.35K
- Average Volume
- 1.78M
- Market Capitalization
- $7.99B
- P/E Ratio
- -13.99
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $41.23
- Year Low
- $14.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.09
Analyst Consensus Summary
Consensus Rating
Sell
23 Analysts
Rating Score
2/5
Recommendation Strength
Upside/Downside
-2.8%
vs Current Price
Price Target
$40.00
Average TargetPrice Target Range
Lowest Target
$40.00
-2.8% DOWNSIDE
Average Target
$40.00
Median Estimate
Highest Target
$40.00
-2.8% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 23
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 18 | 4 | 1 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| H.C. Wainwright | Douglas Tsao | $40 | $35.56 | 2026-05-21 06:35 AM | 12.5% |
| Guggenheim | Yatin Suneja | $41 | $26.2689 | 2025-12-18 08:29 AM | 56.1% |
| H.C. Wainwright | Douglas Tsao | $51 | $30.2 | 2024-09-10 02:40 AM | 68.9% |
| Oppenheimer | Leland Gershell | $46 | $25.39 | 2024-06-03 03:22 AM | 81.2% |
| Guggenheim | Yatin Suneja | $48 | $26.41 | 2024-05-30 10:40 AM | 81.7% |
| Piper Sandler | Yasmeen Rahimi | $57 | $27.83 | 2024-05-30 03:41 AM | 104.8% |
| Goldman Sachs | Corinne Johnson | $50 | $31.82 | 2024-03-13 01:29 AM | 57.1% |
| UBS | Colin Bristow | $5 | $4.88 | 2022-09-26 01:29 AM | 2.5% |